Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 177 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Viagra (sildenafil citrate) Clear all
Completed Phase 2 Interventional Results available

Safety of Sildenafil in Premature Infants

NCT03142568
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945
View directory record Official record
Conditions
Obesity
Interventions
Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 7, 2026, 8:03 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy

NCT03406169
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Sildenafil 25 MG Oral Tablet, Pentoxifylline, Placebo
Drug · Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
30 Years to 89 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609
View directory record Official record
Conditions
NAFLD
Interventions
Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 7, 2026, 8:03 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Use of Sildenafil for Treatment of Urinary Incontinence

NCT02983461
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

NCT01290484
View directory record Official record
Conditions
Lymphangioma
Interventions
Sildenafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Improving Right Ventricular Function in Young Adults Born Preterm

NCT03696758
View directory record Official record
Conditions
Infant,Premature
Interventions
Pulmonary Function Testing, Electrocardiogram, Cardiac Magnetic Resonance Imaging, Metoprolol, Sildenafil
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204
View directory record Official record
Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 7, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy

NCT00511498
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sildenafil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 7, 2026, 8:03 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Microvasculopathy in Chronic TBI

NCT05782244
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate low dose, Placebo, Sildenafil medium dose, Sildenafil high dose
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 8:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury

NCT04820881
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 7, 2026, 8:03 AM EDT
Terminated Phase 4 Interventional Results available

Chronic Sildenafil for Severe Diaphragmatic Hernia

NCT00133679
View directory record Official record
Conditions
Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
Interventions
sildenafil, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Days to 42 Days
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 7, 2026, 8:03 AM EDT
Recruiting Early Phase 1 Interventional

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

NCT06510322
View directory record Official record
Conditions
Vascular Diseases
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

NCT00057759
View directory record Official record
Conditions
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction, Sexuality and Reproductive Issues
Interventions
sildenafil citrate, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
30
States / cities
Concord, California • Inglewood, California • Walnut Creek, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 2 Interventional

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

NCT00080808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alprostadil (E1), Papaverine, Phentolamine mesylate, Sildenafil citrate, conventional surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 7, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Results available

Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?

NCT02908490
View directory record Official record
Conditions
Arthritis, Rheumatoid, Atherosclerosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Kimberly Liang
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.

NCT00734604
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Huntsville, Alabama • Newport Beach, California • Middlebury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

NCT00517933
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil Citrate, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

NCT02466802
View directory record Official record
Conditions
Solid Tumor
Interventions
Regorafenib, Sildenafil Citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 7, 2026, 8:03 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 7, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 7, 2026, 8:03 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1

NCT04770155
View directory record Official record
Conditions
Vascular Function, Racial Disparity
Interventions
Dietary Nitrates 400 mg, L-citrulline 3 g, Sildenafil 100 mg, Bosentan 125 mg
Dietary Supplement · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 7, 2026, 8:03 AM EDT